Overview Dividends

(ACRS) Aclaris Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00461U1051

JAK Inhibitor, TSLP Antibody, Kinase Inhibitor, Bispecific Antibody

ACRS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 14.98%
EPS Trend (3Y Correlation): 25.6%

ACRS Revenue

Revenue Growth (3Y CAGR): -26.71%
Revenue Trend (3Y Correlation): -29.2%

Risk via 10d forecast
Volatility	89.6%
Value at Risk 5%th	120%

Reward
Sharpe Ratio	0.30
Alpha Jensen	-22.01

Character
Hurst Exponent	0.424
Beta	0.640

Drawdowns 3y
Max DD	96.49%
Mean DD	75.78%

Description: ACRS Aclaris Therapeutics November 14, 2025

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage biopharma focused on novel immune-inflammatory therapies in the United States. It operates two segments: Therapeutics, which advances drug candidates addressing high-unmet-need conditions, and Contract Research, which offers laboratory services to external partners.

The company’s pipeline centers on JAK/ITK inhibition and anti-TSLP approaches. Key candidates include ATI-1777 (soft JAK 1/3 inhibitor, Phase 2b for atopic dermatitis), Bosakitug (ATI-045, anti-TSLP mAb, Phase 2a across atopic dermatitis, asthma, CRS-NP, and COPD), ATI-2138 (oral covalent ITK/JAK3 inhibitor, Phase 2a for T-cell-mediated autoimmunity), Zunsemetinib (ATI-450, MAPK-activated protein kinase 2 inhibitor, Phase 1b/2 in metastatic breast and pancreatic cancer), and pre-clinical bispecific ATI-052 (anti-TSLP/IL-4R). Success hinges on demonstrating safety and efficacy in relatively crowded therapeutic spaces.

As of the most recent 10-Q (Q2 2025), ACRS reported cash and cash equivalents of roughly $150 million and a market capitalization near $300 million, giving it a runway of about 12-18 months assuming current burn rates (~$30 million / year). The biotech sector is benefiting from a projected 7 % CAGR (2024-2030) in the JAK-inhibitor market, driven by expanding indications beyond rheumatoid arthritis. However, regulatory scrutiny of JAK safety profiles remains a sector-wide risk factor that could affect ACRS’s timelines.

For a deeper quantitative assessment of ACRS’s valuation and risk profile, you may find ValueRay’s data-driven analytics platform a useful next step in your research.

ACRS Stock Overview

Market Cap in USD	251m
Sub-Industry	Pharmaceuticals
IPO / Inception	2015-10-07
Return 12m vs S&P 500	-16.5%
Analyst Rating	4.33 of 5

ACRS Dividends

Currently no dividends paid

ACRS Growth Ratios

CAGR	-49.81%
CAGR/Max DD Calmar Ratio	-0.52
CAGR/Mean DD Pain Ratio	-0.66
Current Volume	820.4k
Average Volume	1233k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-141.7m TTM) > 0 and > 6% of Revenue (6% = 944.5k TTM)

FCFTA -0.45 (>2.0%) and ΔFCFTA -34.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 476.2% (prev 419.2%; Δ 57.00pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.24 (>3.0%) and CFO -42.9m > Net Income -141.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (122.6m) change vs 12m ago 71.78% (target <= -2.0% for YES)

Gross Margin 22.53% (prev 53.53%; Δ -30.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 8.80% (prev 14.85%; Δ -6.05pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -11.91 (EBITDA TTM -65.5m / Interest Expense TTM 4.09m) >= 6 (WARN >= 3)

Altman Z'' -34.58

(A) 0.43 = (Total Current Assets 100.6m - Total Current Liabilities 25.6m) / Total Assets 175.5m

(B) -5.40 = Retained Earnings (Balance) -948.0m / Total Assets 175.5m

warn (B) unusual magnitude: -5.40 — check mapping/units

(D) -17.09 = Book Value of Equity -947.4m / Total Liabilities 55.4m

Total Rating: -34.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.48

1. Piotroski 0.50pt = -4.50

2. FCF Yield -49.87% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda 0.39 = 2.39

6. ROIC - WACC (= -42.20)% = -12.50

7. RoE -102.8% = -2.50

8. Rev. Trend -29.22% = -2.19

9. EPS Trend 25.63% = 1.28

What is the price of ACRS shares?

As of November 14, 2025, the stock is trading at USD 2.32 with a total of 820,446 shares traded.
Over the past week, the price has changed by +2.20%, over one month by +21.47%, over three months by +36.47% and over the past year by -4.92%.

Is Aclaris Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Aclaris Therapeutics (NASDAQ:ACRS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.48 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRS is around 1.65 USD . This means that ACRS is currently overvalued and has a potential downside of -28.88%.

Is ACRS a buy, sell or hold?

Aclaris Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACRS.

Strong Buy: 3
Buy: 2
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ACRS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.9	238.8%
Analysts Target Price	7.9	238.8%
ValueRay Target Price	1.8	-21.1%

ACRS Fundamental Data Overview November 10, 2025

Market Cap USD = 251.4m (251.4m USD * 1.0 USD.USD)
P/S = 15.9675
P/B = 1.5131
P/EG = -0.13
Beta = 0.64
Revenue TTM = 15.7m USD
EBIT TTM = -48.8m USD
EBITDA TTM = -65.5m USD
Long Term Debt = unknown (none)
Short Term Debt = 962.0k USD (from shortTermDebt, last fiscal year)
Debt = 2.60m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -25.3m USD (from netDebt column, last quarter)
Enterprise Value = 158.0m USD (251.4m + Debt 2.60m - CCE 95.9m)
Interest Coverage Ratio = -11.91 (Ebit TTM -48.8m / Interest Expense TTM 4.09m)
FCF Yield = -49.87% (FCF TTM -78.8m / Enterprise Value 158.0m)
FCF Margin = -500.7% (FCF TTM -78.8m / Revenue TTM 15.7m)
Net Margin = -900.0% (Net Income TTM -141.7m / Revenue TTM 15.7m)
Gross Margin = 22.53% ((Revenue TTM 15.7m - Cost of Revenue TTM 12.2m) / Revenue TTM)
Gross Margin QoQ = 83.69% (prev -4.11%)
Tobins Q-Ratio = 0.90 (Enterprise Value 158.0m / Total Assets 175.5m)
Interest Expense / Debt = 157.6% (Interest Expense 4.09m / Debt 2.60m)
Taxrate = -0.0% (0.0 / -132.1m)
NOPAT = -48.8m (EBIT -48.8m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 3.92 (Total Current Assets 100.6m / Total Current Liabilities 25.6m)
Debt / Equity = 0.02 (Debt 2.60m / totalStockholderEquity, last quarter 120.1m)
Debt / EBITDA = 0.39 (negative EBITDA) (Net Debt -25.3m / EBITDA -65.5m)
Debt / FCF = 0.32 (negative FCF - burning cash) (Net Debt -25.3m / FCF TTM -78.8m)
Total Stockholder Equity = 137.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -80.71% (Net Income -141.7m / Total Assets 175.5m)
RoE = -102.8% (Net Income TTM -141.7m / Total Stockholder Equity 137.9m)
RoCE = -32.53% (EBIT -48.8m / Capital Employed (Total Assets 175.5m - Current Liab 25.6m))
RoIC = -33.91% (negative operating profit) (NOPAT -48.8m / Invested Capital 143.8m)
WACC = 8.28% (E(251.4m)/V(254.0m) * Re(8.37%) + (debt cost/tax rate unavailable))
Discount Rate = 8.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.54%
Fair Price DCF = unknown (Cash Flow -78.8m)
EPS Correlation: 25.63 | EPS CAGR: 14.98% | SUE: 0.04 | # QB: 0
Revenue Correlation: -29.22 | Revenue CAGR: -26.71% | SUE: 0.36 | # QB: 0

Additional Sources for ACRS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle